Returns | 1W : 10.5% , 1M : 33.7%,1Y : 563% |
LT :   |
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
NEULAND LABORATORIES | 10.5% | 33.7% | 563% |
SUN PHARMACEUTICAL INDUSTRIES | 1.2% | 11.4% | 36.3% |
DR REDDYS LABORATORIES | 7.4% | 23.5% | 34.1% |
DIVIS LABORATORIES | -0.8% | 14.8% | 61.7% |
CIPLA | 3.3% | 25.1% | 62.3% |
BIOCON | -1.2% | 2.6% | 12.1% |
AUROBINDO PHARMA | 8.6% | 23.1% | 82.7% |
LUPIN | 1.1% | 6.1% | 34.7% |
TORRENT PHARMACEUTICALS | 0.4% | 8.8% | 11.6% |
Ratio | Value |
---|---|
P/E P/B P/S |
215
P/E Calculated based on EPS of 12.38
[ Mar2020 - Standalone Results ] 4.85
P/B Calculated based on Book Value of 549.21
[ Mar2020 - Standalone Results ] 4.33
P/S Calculated based on Revenues of 787.128 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
326% 234% 264% |
Pledged Shares |
4.3 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 3.7% | 15.3% | 56.9% |
S&P BSE SMALL CAP | 0.5% | 2.5% | 90.8% |
S&P BSE MIDSMALLCAP | 0.2% | 1.7% | 80% |
S&P BSE ALLCAP | -0.8% | -0.3% | 59.7% |